Skip to main content
. 2020 Mar 2;12(4):e11177. doi: 10.15252/emmm.201911177

Figure EV3. RSK1/2 specifically regulates EphA2‐GPRC5A signaling axis.

Figure EV3

  • A
    Heat map for RSK1 (RPS6KA1), RSK2 (RPS6KA3), RSK3 (RPS6KA2), and RSK4 (RPS6KA4) mRNAs in OVCAR4, OVCAR8, and TYK‐nu. The cells expressed most prominently RSK1/2 over RSK3/RSK4. Data obtained from the Cancer Cell Line Encyclopedia (https://portals.broadinstitute.org/ccle) and illustrated per cell line. See Appendix Table S8 for probe IDs.
  • B
    EphA2, RSK1, and RSK2 protein levels and EphA2 phosphorylation as indicated in RSK1/2‐depleted and cisplatin‐treated OC cells 5 days after transfection. OVCAR4 was treated with 0–5 μM and OVCAR8 with 0–10 μM cisplatin for 72 h. Asterisk indicates unspecific band.
  • C, D
    Cell viability of RSK1 and RSK2 overexpressing OVCAR4 (C; N = 4) and OVCAR8 (D; N = 3) after treatment with 0–20 µM cisplatin for 72 h.
  • E, F
    Viability of OVCAR4 overexpressing GPRC5A (E; N = 4) or EphA2 (F; N = 3) after treatment with 0–10 µM cisplatin for 72 h.
Data information: In (C–F), data are presented as mean (SD). *P < 0.05, **P < 0.01, ***P < 0.001. Exact P‐values are provided in Appendix Table S10, Student's t‐test.Source data are available online for this figure.